PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.23
Both firms show negative OCF/share. Martin Whitman would suspect an industry-wide challenge or high growth burn rates.
-0.23
Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.
-1.33%
Both companies show negative capex-to-OCF ratios. Martin Whitman would see if the sector is unprofitable or if accounting anomalies exist.
0.91
1.25–1.5x GNPX's 0.74. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.
-1723.31%
Negative ratio while GNPX is 0.00%. Joel Greenblatt would see if the company’s revenues or cash flows are fundamentally flawed.